Study guide
15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
Key Takeaways Explain This Topic AI
European guidance diagnoses urethritis in men from 5 or more polymorphonuclear leucocytes per high-power field on a urethral smear, whereas US guidance uses 2 or more.
Mycoplasma genitalium should be tested only in symptomatic patients and their partners, using a NAAT with a macrolide resistance assay, rather than by screening asymptomatic people.
For macrolide-resistant Mycoplasma genitalium, European guidance recommends moxifloxacin 400 mg daily for 7 days, and a test of cure is advised no earlier than 3 weeks after starting treatment.
Bacterial vaginosis is diagnosed by at least 3 of 4 Amsel criteria (thin homogeneous discharge, vaginal pH over 4.5, positive amine whiff test, clue cells) or a Nugent score of 7 to 10.
Recurrent vulvovaginal candidiasis, meaning 4 or more episodes a year, is treated with induction therapy followed by weekly oral fluconazole 150 mg for 6 months.
Last updated: September 2026
15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
The official venereology syllabus covers the "clinical diagnosis and management of STIs, including systemic manifestations, genito-anal dermatoses and the local and systemic complications", plus laboratory diagnosis. This section adds the infections not covered in the syphilis, gonorrhoea, chlamydia, and genital ulcer sections. European IUSTI guidelines are used first.
Urethritis in Men
Urethritis causes dysuria and urethral discharge, but it can be asymptomatic.
Confirm urethral inflammation with a Gram- or methylene blue-stained urethral smear. European and UK guidance uses ≥ 5 polymorphonuclear leucocytes (PMNL) per high-power field ; the US CDC uses ≥ 2 . A first-void urine sediment can also be used.
Gonococcal urethritis: Gram-negative intracellular diplococci on the smear; see the gonorrhoea section.
Non-gonococcal urethritis (NGU): causes include Chlamydia trachomatis (the most common), Mycoplasma genitalium , Trichomonas vaginalis , adenovirus (with conjunctivitis), herpes simplex virus, and Neisseria meningitidis (after oral sex). The role of Ureaplasma urealyticum is uncertain. Many cases have no identified pathogen.
Empirical treatment of NGU: doxycycline 100 mg twice daily for 7 days is preferred. Single-dose azithromycin 1 g is no longer favoured because it selects macrolide resistance in M. genitalium .
Test for gonorrhoea, chlamydia, and M. genitalium with NAATs, and offer HIV and syphilis testing. Treat and test partners, and advise no sex until treatment is complete.
Mycoplasma genitalium
M. genitalium causes urethritis in men and cervicitis, pelvic inflammatory disease (PID), and possibly infertility in women. It lacks a cell wall (so beta-lactams do not work) and rapidly acquires resistance to macrolides and fluoroquinolones.
Testing (European guidance):
Test symptomatic patients (urethritis, cervicitis, PID, epididymitis, proctitis) and current partners of infected patients.
Do not screen asymptomatic people , because treatment drives resistance and the benefit is unclear.
Use a NAAT followed by a macrolide resistance-associated mutation assay (23S rRNA gene).
Resistance-guided treatment:
- Situation Treatment
- Macrolide-susceptible Azithromycin 500 mg on day 1, then 250 mg on days 2–5 (total 1.5 g)
- Macrolide-resistant , or failure after azithromycin Moxifloxacin 400 mg daily for 7 days (longer for PID)
- Failure of both Pristinamycin or minocycline in specialist centres
Some guidelines, for example in the UK, give doxycycline first to lower the bacterial load before the targeted antibiotic. A test of cure is advised no earlier than 3 weeks after starting treatment.
Trichomoniasis
Trichomonas vaginalis is a flagellated protozoan.
Women: frothy yellow-green offensive discharge, vulvovaginal soreness, and sometimes a "strawberry cervix" (colpitis macularis); vaginal pH is above 4.5. Many are asymptomatic.
Men: usually asymptomatic, sometimes urethritis.
Diagnosis: NAAT is the most sensitive test. Wet-mount microscopy of motile trichomonads is quick but misses many cases.
Treatment: metronidazole 500 mg twice daily for 7 days (the preferred regimen, especially for women), or a single 2 g dose as an alternative. Treat partners at the same time, and test for other STIs. Metronidazole can be used in pregnancy. Patients are usually advised to avoid alcohol during treatment.
Bacterial Vaginosis (BV)
BV is a change in vaginal flora, with loss of Lactobacillus and overgrowth of anaerobes ( Gardnerella , Fannyhessea (Atopobium) vaginae , and others). It is associated with sexual activity but is not classed as a classic STI.
Amsel criteria (at least 3 of 4): thin, white-grey, homogeneous discharge; vaginal pH above 4.5 ; a positive "whiff" test (fishy amine smell when potassium hydroxide is added); and clue cells on microscopy.
Nugent score (Gram stain): 7–10 indicates BV.
Treatment of symptomatic BV: oral metronidazole for 5–7 days, metronidazole gel for 5 days, or clindamycin cream for 7 days. Recurrence is common. Routine treatment of male partners is not recommended.
BV in pregnancy is linked to preterm birth and late miscarriage.
Vulvovaginal Candidiasis (VVC)
Cause: Candida albicans in about 90% of cases; non-albicans species such as C. glabrata are harder to treat.
Clinical: itch, soreness, and thick white "cottage cheese" discharge; vaginal pH is normal (4.5 or below) .
Treatment: a single clotrimazole 500 mg pessary or fluconazole 150 mg orally . In pregnancy, use topical azoles for 7 days only.
Recurrent VVC (4 or more episodes a year): confirm with culture, check for diabetes and other factors, then give induction therapy followed by weekly fluconazole 150 mg for 6 months .
Balanitis and Balanoposthitis
- Type Features
- Candidal Itchy red glans with small papules and pustules; associated with diabetes and SGLT2 inhibitors
- Anaerobic Foul-smelling discharge and oedema; metronidazole
- Streptococcal Sharply defined red balanitis; swab and give penicillin
- Irritant / contact Over-washing, soaps, latex, or lubricants
- Circinate balanitis Painless serpiginous erosions in reactive arthritis
- Zoon balanitis, lichen sclerosus, penile intraepithelial neoplasia See their own sections
- Other Syndromes
Epididymo-orchitis: in younger sexually active men it is usually caused by C. trachomatis or N. gonorrhoeae (treat with ceftriaxone plus doxycycline). In older men and after instrumentation, enteric organisms such as E. coli are more likely (treat with a fluoroquinolone). Always exclude testicular torsion , which is a surgical emergency.
Pelvic inflammatory disease: lower abdominal pain, deep dyspareunia, cervical motion tenderness, and fever. Treat promptly on clinical suspicion with a single IM ceftriaxone dose plus doxycycline and metronidazole for 14 days , and treat partners. Complications are infertility, ectopic pregnancy, and chronic pelvic pain. Perihepatitis is Fitz-Hugh-Curtis syndrome .
Proctitis: anal pain, discharge, tenesmus, and bleeding after receptive anal sex. Causes include gonorrhoea, chlamydia (especially LGV ), herpes simplex virus, and syphilis. Take rectal NAAT swabs, and treat empirically for gonorrhoea and chlamydia (doxycycline for 3 weeks if LGV is suspected).
Sexually Transmitted Hepatitis
- Virus Sexual Transmission Notes Prevention
- Hepatitis A Oro-anal contact; outbreaks among men who have sex with men Vaccination for at-risk groups
Hepatitis B Efficient sexual transmission; test for HBsAg, anti-HBc, and anti-HBs Vaccination for MSM, sex workers, people who inject drugs, and partners of carriers
Hepatitis C Mainly blood-borne; sexual transmission among MSM with HIV , linked to chemsex and traumatic sex Regular testing in at-risk groups; direct-acting antivirals cure most infections